Israeli commercial-stage medical device company Body Vision Medical, a firm specializing in lung cancer diagnostics and treatment through real-time software technologies, announced last week that it had completed a $20 million Series C funding round.
No details about who led the round were disclosed but its proceeds will be used to streamline commercialization and manufacturing activities for Body Vision’s LungVision 2.0 platform, a statement said.
Founded in 2014, the Ramat HaSharon-based company has raised a total of $34.5 million to date, according to Start-Up Nation Finder, including a round where the company raised $8.5 million.
Their LungVision 2.0 platform, which received FDA clearance in May 2019, is designed to enable the pulmonologist with easy and instant access to advanced technological capabilities, within their regular procedure room, says Dorian Averbuch, Body Vision Medical founder and CEO.
“Seamlessly integrated into the standard procedure flow, the LungVision platform offers continuous support throughout all phases of a Navigation Bronchoscopy procedure. This platform includes precise tomographic tool-in-lesion confirmation and guided biopsy sampling. Body Vision Medical is uniquely equipped to provide both the physician and hospital with highly desired benefits through continuous delivery of cost-effective medical procedures,” she said.
The platform features AI Tomography, fused imaging, cloud-based machine learning and multi-modality image registration.